发明名称 |
CELL PENETRATING ANTI-GUANOSINE ANTIBODY BASED THERAPY FOR CANCERS WITH RAS MUTATIONS |
摘要 |
It has been established that cancer cells with oncogenic mutants in the small GTPase K-Ras are susceptible to antibodies that bind intracellular guanosine, but delivery of antibodies into cells can be challenging. A subset of lupus autoantibodies is associated with anti-guanosine activity, and is capable of cellular penetration. These antibodies have potential as therapeutic agents targeted towards K-Ras associated malignancies. |
申请公布号 |
US2017073429(A1) |
申请公布日期 |
2017.03.16 |
申请号 |
US201515123195 |
申请日期 |
2015.03.04 |
申请人 |
Yale University ;The United States Govemment as represented by The Department of Veterans Affairs |
发明人 |
Hansen James E.;Weisbart Richard H.;Young Melissa;Noble Philip W. |
分类号 |
C07K16/40;A61K45/06;A61K39/395 |
主分类号 |
C07K16/40 |
代理机构 |
|
代理人 |
|
主权项 |
1. A pharmaceutical composition comprising
a) one or more cell-penetrating anti-guanosine antibodies or antigen binding fragments or fusions or variants thereof in an amount effective to prevent, reduce or inhibit the growth or proliferation of cells having one or more amino acid mutations in the small GTPase K-Ras; and b) a sterile pharmaceutically acceptable excipient for administration to a human. |
地址 |
New Haven CT US |